Clinical Rationale for Early AOM Intervention Traditional obesity management often follows a fixed-duration behavioral therapy (BT) approach before considering medication, yet mounting evidence suggests this may not be optimal for many patients
Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice
References Bayliss, W
That's a reason to keep on top of your nutrition and strength-training while on these drugs, he writes, "especially for older people like me, who are [already] susceptible to muscle loss." There are people who should steer clear of GLP-1 drugs, Kessler notes, including those with a personal or familial history of certain thyroid and endocrine cancers, those with chronic kidney disease, pancreatitis, inflammatory bowel diseases, uncontrolled diarrhea or constipation or gastroparesis, or if you are pregnant
Retrieved from National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
&srotate=0)
